Test Directory

Test Code
1487
Test Name
Bethlem Myopathy & Ullrich Congenital Muscular Dystrophy NGS Panel
CPT Codes
81479
Expected Turnaround Time
Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited.
Clinical Utility
Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members.
Specimen and Container Info

Non-Prenatal Specimens

Preferred/Alternate

Specimen Type

Containers

Volume

Preferred Specimen Type

Whole Blood

Lavender Top (EDTA)

3 mL

Alternate Specimen Type

Genomic DNA

1.5 mL Tube

3 µg (at a concentration of at least 30 ng/µl), preferably in TE solution.

Alternate Specimen Type

Fibroblasts

T-25 Flasks

2 confluent T-25 flasks, filled to capacity

Alternate Specimen Type

Saliva (Whole blood is recommended for CNV)

DNA Self-Collection Kit or Oragene Saliva Collection Kit for Young Children

Follow kit instructions (www.dnagenotek.com)

Prenatal Specimens

Either specimen type below is acceptable.

Specimen Type

Containers

Volume

Cultured cells

T-25 Flasks

2 confluent T-25 flasks derived from amnio or CVS samples.

Genomic DNA

1.5 mL Tube

3 µg (at a concentration of at least 30 ng/µl), preferably in TE solution.

NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico.

Transport Instructions
  • Transport at room temperature within 24 hours.
  • If the specimen cannot be transported to the lab within 24 hours, refrigerate for up to 72 hours.
  • Do not freeze or expose to extreme temperatures, refrigerate for up to 72 hours if cannot be transported to lab within 24 hours. 
Stability Requirements

Room Temperature

24 hours

Refrigerated

72 hours

Causes for Rejection
  • Improperly labeled specimen (minimum of two patient identifiers)
  • Inappropriate specimen type
  • Incomplete or incorrect test request form
  • Insufficient volume
  • Specimen has leaked in transit
  • Specimen without a test order
Methodology
Next Generation Sequencing and Copy Number Variation Analysis
Performing Location
Genomics - Snowdrift
Alternate Names
  • BTHLM1
  • BTHLM2
  • UCMD2
Description

Bethlem myopathy 1 (BTHLM1; MIM 158810) and Ullrich congenital muscular dystrophy 1 (UCMD2; MIM 254090) are two related disorders caused by mutations in the COL6A1, COL6A2 or COL6A3 gene. Bethlem myopathy 2 (BTHLM2; MIM 616471) and Ullrich congenital muscular dystrophy 2 (UCMD2; MIM 616470) are caused by mutations in the COL12A1 gene.

Bethlem myopathy is an autosomal dominant disorder characterized by mild to moderate proximal muscular weakness and mild muscle atrophy. Contractures of the elbows, ankles, and flexion contractures of the last four fingers are present and range in severity. There may be moderate weakness of the trunk muscles and diaphragm. The age of onset ranges from birth to adulthood. The disorder is slowly progressive and about one half of the patients require ambulatory support after the fifth decade.

Ullrich congenital muscular dystrophy was originally described as an autosomal recessive disorder, but heterozygous dominant negative mutations have also been described. Ullrich congenital muscular dystrophy is more severe than Bethlem myopathy and is characterized by neonatal hypotonia, severe muscular weakness, and generalized muscular atrophy. Patients with Ullrich congenital muscular dystrophy have delayed motor milestones and difficulty with ambulation. Patients also present with proximal joint contractures, spinal rigidity, scoliosis, kyphosis, and distal joint laxity. Weakness of the trunk muscles and diaphragm can lead to respiratory insufficiency. Ullrich congenital muscular dystrophy is progressive and many patients lose the ability to ambulate.

Testing Schedule
Monday-Friday
Genes
COL12A1, COL6A1, COL6A2, COL6A3
Disease Group
Neuromuscular